Ace the Case Challenge Series: Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk

Effectively managing high cholesterol level and safely lowering LDL-C is crucial for preventing and reducing the risk of adverse cardiovascular events. However, achieving LDL-C goals remains suboptimal, particularly in high-risk and very high-risk patients. The landscape of lipid lowering therapy has significantly evolved, with new consensus statements, newer agents, and important evidence that may help address some current gaps.

This three part series consists of 3 cases that illustrate important concepts in managing patients with familial hypercholesterolemia, patients with hyperlipidemia and cardiometabolic comorbidities, and patient with South Asian descent with increased risk of ASCVD and a history of percutaneous Intervention. The cases are designed to be quick and offer high-level takeaways and pearls.

Case #1: A 34-Year-Old Woman with Severe Heterozygous Familial Hypercholesterolemia (HeFH)
Case #2: A 62-Year-Old Woman with Diabetes with an LDL-C of 53 mg/dL
Case #3: A 54-Year-Old South Asian Male with a History of Cardiac Percutaneous Intervention

Target Audience

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

Learning Objectives

After completing this activity, the participant should be better able to:

Identify patients with statin intolerance who may benefit from non-statin therapies.
Recognize the need for the early and adequate intensification of LDL-C lowering therapy beyond statins to address ASCVD risk.
Review the benefit of newer treatment options for LDL-C lowering that can help increase patient adherence to therapy.
Select individualized treatment strategies for LDL-C lowering that prioritize the early initiation and intensification of therapy to reduce ASCVD risk according to current guidelines and evidence.

Course summary

Available credit:

0.75 ACPE Pharmacy
0.75 AMA PRA Category 1 Credit™
0.75 ANCC
0.75 Participation

Course opens:

06/12/2024

Course expires:

06/12/2025

Rating:

Christie M. Ballantyne, MD
Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Houston, TX

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Paul V. Kramer Chair of Cardiovascular Disease Prevention
Director, Seinsheimer Cardiovascular Health Program
The Medical University of South Carolina
Charleston, SC

Pam R. Taub, MD, FACC
Founder and Director of Step Family Cardiac Rehabilitation and Wellness Center
Professor of Medicine
UC San Diego Health System
San Diego, CA

All CME information can be found within each case. Once you enroll into this series, please visit the last tab of this page "Take Course" to select and start a patient Ace the Case activity.